Henrik Sengeloev
Overview
Explore the profile of Henrik Sengeloev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
339
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luft T, Gras L, Koster L, Kroger N, Schroder T, Platzbecker U, et al.
Am J Hematol
. 2024 Nov;
100(1):38-51.
PMID: 39605194
Prophylaxis strategies for Graft versus host disease (GVHD) in allogeneic hematopoietic cell transplantation (allo-HCT) frequently encompass a combination of a calcineurin inhibitor (CNI) with either methotrexate (MTX) or mycophenolate mofetil...
2.
Orti G, Peczynski C, Boreland W, OReilly M, von Bonin M, Balduzzi A, et al.
Leukemia
. 2024 Nov;
39(2):431-437.
PMID: 39562721
In patients diagnosed with B-acute lymphoblastic leukemia (B-ALL) or B-non-Hodgkin's lymphoma (B-NHL) relapsing after allogeneic stem cell transplantation (allo-HCT), it is a standard practice to perform anti-CD19 chimeric antigen receptor...
3.
Larue M, Labopin M, Schroeder T, Huang X, Blau I, Schetelig J, et al.
Hemasphere
. 2024 Oct;
8(10):e70026.
PMID: 39440198
Information on late complications in patients with acute leukemia who have undergone allogeneic hematopoietic cell transplantation (HCT) is limited. We performed a left-truncated analysis of long-term survival in patients with...
4.
Nagler A, Ngoya M, Galimard J, Labopin M, Blau I, Kroger N, et al.
Am J Hematol
. 2024 Jun;
99(9):1732-1745.
PMID: 38856236
We compared relapse incidence (RI) post-unrelated transplantation with post-transplant cyclophosphamide (PTCy) versus no PTCy graft-versus-host disease (GVHD) prophylaxis, in 7049 acute myeloid leukemia (AML) patients in remission, 707 with PTCy,...
5.
Scheid C, Eikema D, van Gelder M, Salmenniemi U, Maertens J, Passweg J, et al.
Blood
. 2024 May;
144(4):445-456.
PMID: 38728380
In patients with myelodysplastic syndrome (MDS), higher revised International Prognostic Scoring System (IPSS-R) scores at transplant are associated with worse transplant outcome and, thus, lowering IPSS-R scores by therapeutic intervention...
6.
Montoro J, Eikema D, Tuffnell J, Potter V, Kalwak K, Halkes C, et al.
Blood
. 2024 Apr;
144(3):323-333.
PMID: 38643511
Selecting the most suitable alternative donor becomes challenging in severe aplastic anemia (SAA) when a matched sibling donor (MSD) is unavailable. We compared outcomes in patients with SAA undergoing stem...
7.
Donor genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight
Schetelig J, Baldauf H, Heidenreich F, Hoogenboom J, Spellman S, Kulagin A, et al.
Front Immunol
. 2024 Apr;
15:1350470.
PMID: 38629074
Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). The donor's Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important information in this regard....
8.
Onida F, Gras L, Ge J, Koster L, Hamladji R, Byrne J, et al.
Br J Haematol
. 2024 Apr;
204(6):2365-2377.
PMID: 38577874
Allogeneic haematopoietic cell transplantation (allo-HCT) remains an option for tyrosine kinase inhibitor-resistant chronic myeloid leukaemia (CML) in first chronic phase (CP1) and high-risk patients with advanced disease phases. In this...
9.
Bazarbachi A, Labopin M, Moukalled N, Kroger N, Rautenberg C, Schetelig J, et al.
Clin Cancer Res
. 2024 Mar;
30(9):1778-1787.
PMID: 38514469
Purpose: Acute myeloid leukemia (AML) is a disease of older patients. Progress in allogeneic hematopoietic cell transplantation (allo-HCT) allowed the delivery of allo-HCT to older patients. We assessed changes over...
10.
Guieze R, Eikema D, Koster L, Schetelig J, Sengeloev H, Passweg J, et al.
Bone Marrow Transplant
. 2024 Mar;
59(7):950-956.
PMID: 38503942
Management of Richter transformation (RT) is particularly challenging, with survival estimates <1 year. We report on outcomes of 66 RT patients undergoing allogeneic-HCT (allo-HCT) between 2008 and 2018 registered with...